drugset / Trial / NCT07317154
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Timeline
- Start
- 2026-09
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell | Cell therapy | — | Other |